Yes, and another rival going down the 'dystrophin' route.
...and targeting a small subset of DMD boys (13%)...same as Sarepta's Exondys51.
PepGen stated goal is to raise 'wild-type dystrophin' to between 10-12%.
BUT we know from Sraepta's results that:
...the additional dystrophin does not stop inflammation...in fact it may increase 'matrix deposition' / fibrosis as the body responds to the new 'wild-type' dystrophin.
Biggest take away from me is the $113m CR...lots of Biotech $$$ looking for projects.
Big week ahead folks!
.
Yes, and another rival going down the 'dystrophin' route. ...and...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.3¢ |
Change
-0.003(3.95%) |
Mkt cap ! $65.81M | |||
| Open | High | Low | Value | Volume |
| 7.6¢ | 7.6¢ | 7.3¢ | $52.95K | 711.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 145970 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 1991 | 1 |
View Market Depth
| Last trade - 15.18pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
7.3¢ |
Change
-0.003 ( 3.95 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.5¢ | 7.3¢ | 69141 | ||
| Last updated 14.55pm 19/04/2024 ? | |||||
| PER (ASX) Chart |